The Center for New Health Technology in Korea has granted Innovative Technology status to the EOS imaging platform, recognizing EOS as a unique modality worthy of a new reimbursement code with higher coverage than conventional X-rays.
The New Health Technology Assessment Committee observes the safety, effectiveness and cost effectiveness of relevant technologies as well as social, ethical and legal effects. EOS was granted its status on the basis of innovations in dose reduction, simultaneous biplanar scanning and 3D reconstruction capacity.
EOS exam reimbursement levels will be determined in coming years. In the interim, hospitals may determine the amount they will charge for each EOS exam.
Source: EOS imaging
EOS imaging received Korean Food and Drug Administration clearance in 3Q14.